Cost analysis of vein-to-vein CAR T-cell therapy: automated manufacturing and supply chain

A cost model was described using Biosolve to measure the impact of automation and scale-out of a CAR-T manufacturing process, and associated supply chain. The partially automated CAR-T manufacturing process was the most economical configuration by CoGs analysis. However, after scale-out and inclusion of the impact of time by NPC evaluation, the manual CAR-T process became the most cost-effective option to meet an annual demand of 5,000 patients. Key process cost drivers were identified as the viral vector required to introduce CARs into T-cells and QC tests. A sensitivity analysis was undertaken to aid a manufacturer on whether to produce or undertake the latter in-house or outsource. Local and centralized CAR-T supply chain models to treat a peak demand of 5,000 patients were also compared. The cost of treatment to the patient, including supply chain costs, was estimated to be between $78k–$93k. A sensitivity analysis of the supply chain models showed the impact of resource availability, patient demand and lengthening the bottleneck on estimated costs.

Please enter your email to access content Read now